Researchers at Melanoma Institute Australia have reported positive results from two clinical trials, COMBI-AD and CheckMate 238, conducted to stop and prevent melanoma progression.

The international trials demonstrated successful prevention of the spread of the skin cancer in stage III patients whose tumours were removed surgically and had a high risk of disease progression.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Melanoma Institute Australia conjoint medical director professor Georgina Long said: “These results will change the way we treat melanoma patients, as well as their quality of life.

“Until now, stage III melanoma patients who have had their tumours surgically removed have simply had to play the waiting game, to see if their melanoma would metastasise or spread.

“Results from these clinical trials suggest we can stop the disease in its tracks, effectively preventing it from spreading and saving lives.”

"Results from these clinical trials suggest we can stop the disease in its tracks, effectively preventing it from spreading and saving lives."

Subjects in the COMBI-AD trial were administered with dabrafenib and trametinib targeted combination therapy or placebo over a period of 12 months.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Aimed at BRAF positive patients, the combination therapy prevented the recurrence of resected stage III melanoma and improved overall survival.

In the CheckMate 238 trial, high-risk stage III and stage IV patients were given nivolumab or ipilimumab immunotherapy for 12 months.

Irrespective of BRAF mutation status, nivolumab is reported to have minimised the chance of relapse and demonstrated a superior safety profile compared to ipilimumab.

Professor Long further added that based on these results, the disease can be effectively addressed at an earlier stage, in turn decreasing patient anxiety on progression of the cancer to a terminal stage.